Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fludarabine in low-grade lymphoma

A Pigaditou1, A Z Rohatiner, J S Whelan

  • 1ICRF Department of Medical Oncology, St Bartholomews Hospital, London, UK.

Seminars in Oncology
|October 1, 1993
PubMed
Summary

Fludarabine shows activity in low-grade non-Hodgkin's lymphoma, with higher response rates in newly diagnosed patients. Myelosuppression and infection were key toxicities observed in this study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-specific parasite competition: mixed infections of Schistosoma mansoni and S. rodhaini in the definitive host.

Parasitology·2008
Same author

Monoclonal antibodies in the diagnosis of lymphoproliferative diseases of the orbit and orbital adnexae.

Eye (London, England)·2006
Same author

A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.

Leukemia·2005
Same author

CD23 expression in mediastinal large B-cell lymphomas.

Histopathology·2004
Same author

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same author

Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.

British journal of haematology·2001

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Low-grade non-Hodgkin's lymphoma (LG-NHL) is a challenging hematologic malignancy.
  • Conventional treatments for LG-NHL have limitations, necessitating exploration of alternative therapies.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of fludarabine in patients with low-grade non-Hodgkin's lymphoma.
  • To assess fludarabine's role in different clinical settings: first-line therapy, minimal residual disease, and recurrent/resistant disease.

Main Methods:

  • A cohort of 88 patients with LG-NHL received fludarabine (25 mg/m2 daily for 5 days) every 3-4 weeks.
  • Patients were categorized into three groups: newly diagnosed, minimal residual disease, and recurrent/resistant disease.

Related Experiment Videos

Main Results:

  • Overall response rates were 69% in newly diagnosed, 44% in minimal residual disease, and 44% in recurrent/resistant disease groups.
  • Myelosuppression, particularly neutropenia, was the predominant toxicity (55% in previously treated, 31% in newly diagnosed).
  • Five treatment-related deaths occurred due to infection in neutropenic patients.

Conclusions:

  • Fludarabine demonstrates significant activity in low-grade non-Hodgkin's lymphoma across various treatment settings.
  • While effective, fludarabine-induced myelosuppression requires careful monitoring due to infection risks.
  • The precise role of fludarabine in the therapeutic algorithm for LG-NHL warrants further investigation.